Successful reversal of acute vascular rejection in a renal allograft with combined mycophenolate mofetil and tacrolimus as primary immunotherapy

Clinical Transplantation

Volumn 11, Issue 2, 1997, Pages 94-97

  Ahsan, Nasimul ^a,b   Holman, Michael J ^a   Katz, Douglas A ^a   Abendroth, Catherine S ^b   Yang, Harold C ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Kidney transplantation; Mycophenolate mofetil; Tacrolimus; Vascular rejection

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; T LYMPHOCYTE; UNITED STATES; VASCULITIS;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; TACROLIMUS;

EID: 0030887216     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. SALMELA KT, WILLEBRAND EOV, KYLLONEN LEJ et al. Acute vascular rejection in renal transplantation- diagnosis and outcome. Transplantation 1992: 54: 858.
2. DELANEY VB, CAMPBELL WG, NASR SA, MCCUE PA, WARSHAW B, WHELCHEL JD. Efficacy of OKT3 monoclonal antibody therapy in steroid-resistant, predominantly vascular acute rejection. Transplantation 1988: 45: 743.
3. NORMAN DJ, FUNNELL, HENELL K, GOLDSTEIN G. OKT3 for treatment of acute and steroid- and ATG-resistant acute rejection in renal allograft transplantation. Transpl Proc 1985: 6: 2744.
4. MATAS AJ, TELLIS VA, QUINN T et al. ALG treatment of steroid-resistant rejection in patients receiving cyclosporine. Transplantation 1986: 41: 579.
5. DEIERHOI MH, KAUFFMAN RS, HUDSON SL et al. Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center. Ann Surg 1993: 217: 476.
6. JORDAN ML, SHAPIRO R, VIVAS CA et al. FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994: 57: 860.
7. SHAPIRO R, JORDAN ML, SCANTLEBURY VP et al. A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation 1995: 59: 485.
8. SOLLINGER HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995: 60: 225.
9. SOLLINGER HW, BELZER FO, DEIERHOI MH et al. RS-61443 (Mycophenolate Mofetil) - A multicenter study for refractory kidney transplant rejection. Ann Surg 1992: 216: 513.
10. LASKOW DA, DEIERHOI MH, HUDSON SH, ORR CL, CURTIS JJ, DIETHELM AG. The incidence of subsequent acute rejection following the treatment of refractory renal allograft rejection with mycophenolate mofetil (RS 61443). Transplantation 1994: 57: 640.
11. LEE WA, GU L, MIKSZTAL AR, CHU N, LEUNG K, NELON PH. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990: 7: 161.
12. EUGUI EM, ALMQUIST SJ, MULLER CD, ALLISON AC. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991: 33: 161.
13. EUGUI EM, MIRKOVICH A, ALLISON AC. Lymphocyte-selective anti-proliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 1991: 33: 175.
14. ALLISON AC, KOWALSKI WJ, MULLER CJ, WATERS RV, EUGUI EM. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, blocks the glycosylation of adhesion molecules. Transpl Proc 1993: 25 (suppl 2): 67.
15. AZUMA H, BINDER J, HEEMANN U, TULLIUS SG, TINLEY NL. Effects of RS61443 on chronic rejection of rat kidney allografts. Transpl Proc 1995: 27(1): 436.
16. PETER DH, FITTON A, PLOSKER GL, FAULDS D. Tacrolimus: a review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993: 46: 746.
17. LIN CS, BOLTZ RC, SIEKIERKA JJ, SIGAL NH, FK-506 and cyclosporine A inhibit highly similar signal transduction pathways in human T lymphocytes. Cell Immunol 1991: 133: 269.
18. GOLDFELD AE, FLEMINGTON EK, BOUSSIOTIS VA, THEODOS CM, TITUS RG. Transcription of the tumor necrosis factor a gene in rapidly induced by anti-immunoglobulin and blocked by cyclosporine A and FK506 in human B cells. Proc Natl Acad Sci USA 1992: 89: 12198.
19. LIU J, FARMER JD, LANE WS, FRIEDMAN J, WEISSMAN I. Calcineurin is a common target of cyclophilin-cyclosporine and FKBP-FK506 complexes. Cell 1991: 66: 807.
20. MORIKAWA K, OSEKO F, MORIKAWA S. The distinct effects of FK506 on the activation, proliferation, and differentiation of human B lymphocytes. Transplantation 1992: 54: 1025.